Compare TNL & SRRK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TNL | SRRK |
|---|---|---|
| Founded | 1990 | 2012 |
| Country | United States | United States |
| Employees | N/A | 289 |
| Industry | Hotels/Resorts | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.5B | 4.6B |
| IPO Year | 2006 | 2018 |
| Metric | TNL | SRRK |
|---|---|---|
| Price | $68.54 | $40.00 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 8 | 11 |
| Target Price | ★ $77.75 | $55.10 |
| AVG Volume (30 Days) | 635.0K | ★ 1.1M |
| Earning Date | 05-21-2026 | 05-28-2026 |
| Dividend Yield | ★ 3.44% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 3.44 | N/A |
| Revenue | ★ $4,021,000,000.00 | N/A |
| Revenue This Year | $3.51 | N/A |
| Revenue Next Year | $3.70 | $449.79 |
| P/E Ratio | $20.27 | ★ N/A |
| Revenue Growth | ★ 4.06 | N/A |
| 52 Week Low | $37.77 | $22.71 |
| 52 Week High | $81.00 | $49.82 |
| Indicator | TNL | SRRK |
|---|---|---|
| Relative Strength Index (RSI) | 36.54 | 32.95 |
| Support Level | $57.54 | $29.32 |
| Resistance Level | $70.43 | $42.54 |
| Average True Range (ATR) | 2.33 | 2.24 |
| MACD | -0.74 | -0.62 |
| Stochastic Oscillator | 0.13 | 1.77 |
Travel+Leisure Co is a membership and leisure travel company. It provides hospitality services and travel products. The company operates in the segments of Vacation Ownership, which is the key revenue-driving segment, develops, markets and sells vacation ownership interests (VOIs) to individual consumers, provides consumer financing in connection with the sale of VOIs, and provides property management services at resorts, and Travel and Membership which operates a variety of travel businesses, including two vacation exchange brands, Vacation Ownership and Travel and Membership The majority of the revenue is earned from the United States.
Scholar Rock Holding Corp is a biopharmaceutical company focused on improving the lives of children and adults with Spinal Muscular Atrophy and other rare, severe, and debilitating neuromuscular diseases. Its pipeline candidates include apitegromab and a subcutaneous formulation of apitegromab. The clinical-stage pipeline also includes SRK-439, an investigational subcutaneously administered fully human anti-pro/latent myostatin antibody with high inhibitory potency and selectivity toward myostatin, being developed for the treatment of rare neuromuscular diseases. The company also maintains early-stage programs focused on therapies for rare, severe, and debilitating neuromuscular diseases.